Skip to main content
Premium Trial:

Request an Annual Quote

Illumina CFO Says Successful Studies Will Encourage Future GWAS Growth

Premium

By Justin Petrone

While Illumina's array business is on the rebound thanks to demand for its HumanOmni2.5-Quad DNA Analysis BeadChip, the firm believes that in order to restore significant growth in the market for whole-genome genotyping arrays, the first studies that use the new chips must be successful.

Illumina Chief Financial Officer Christian Henry said last week that the third quarter was the strongest for the San Diego firm's array business in more than a year, led by adoption of the Omni2.5. Launched in June, the 2.5M contains common and rare variants from the 1000 Genomes Project, and is available in a four-sample format composed of approximately 10 million markers per array (BAN 6/8/2010).

"It was our best-selling array in the quarter," Henry said, and called the uptake of the chip a "nice indication that people were waiting and there was demand." Henry comments were webcast from the Piper Jaffray Health Care Conference, held last week in New York.

Still, while demand for Illumina's whole-genome genotyping arrays is up, Henry said it is "important for early projects" that rely on the arrays to "show success which will then drive the next wave of GWAS."

He predicted that some data from early studies should become available early next year and into the second quarter."GWAS will continue to grow next year; how fast will be dependent on how these early programs wrap up," he said.

The company also anticipates that should the outcome of these studies be successful, more customers will adopt its Omni5 BeadChip when it becomes available next year. The firm's most recent prediction is that the 5-million-marker array will be commercialized in the middle of 2011 (11/2/2010).

According to Henry, the Omni5 will include a SNP for every 60 bases and will be a "very high-performance chip." He said the firm is also gauging demand for new arrays that will harness rare variant content.

"Customers are asking for more, better, faster," said Henry. "They want to look at rare variant content and they want to look at content that is ethnically focused."
Researchers are currently debating whether it will be wiser to pursue their studies using ethnically themed arrays or to use a more general array (BAN 11/9/2010).

"Ultimately, we will be able to design products that will be specifically focused on ethnicities," Henry said. "We have the flexibility. It depends on what the customer really wants."


Have topics you'd like to see covered in BioArray News? Contact the editor at jpetrone [at] genomeweb [.] com.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.